DNA methylation in stress and depression: from biomarker to therapeutics

Autor(es)

Sales, Amanda J. ^[1] ; Guimaraes, Francisco S. ^{[2, 1]} ; Joca, Samia R. L. ^{[2, 3]}

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Sch Med Ribeirao Preto FMRP, Dept Pharmacol, Av Bandeirantes 3900, BR-14049900 Sao Paulo, SP - Brazil

^[2] Univ Sao Paulo, Ctr Interdisciplinary Res Appl Neurosci NAPNA, Ribeirao Preto, SP - Brazil

^[3] Aarhus Univ, Dept Biomed, Ole Worms Alle 4, DK-8000 Aarhus C - Denmark

• Tipo de documento: Artigo de Revisão
• Fonte: ACTA NEUROPSYCHIATRICA; v. 33, n. 5, p. 217-241, OCT 2021.
• Citações Web of Science: 0

Resumo

Epigenetic mechanisms such as DNA methylation (DNAm) have been associated with stress responses and increased vulnerability to depression. Abnormal DNAm is observed in stressed animals and depressed individuals. Antidepressant treatment modulates DNAm levels and regulates gene expression in diverse tissues, including the brain and the blood. Therefore, DNAm could be a potential therapeutic target in depression. Here, we reviewed the current knowledge about the involvement of DNAm in the behavioural and molecular changes associated with stress exposure and depression. We also evaluated the possible use of DNAm changes as biomarkers of depression. Finally, we discussed current knowledge limitations and future perspectives. (AU)

• Processo FAPESP: 18/15896-3 - Participação da metilação do DNA no efeito antidepressivo rápido e sustentado induzido por Canabidiol e Ketamina
• Beneficiário: Amanda Juliana Sales
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado